Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-γ inhibit keratinocyte proliferation

Archives of Dermatology

Volumn 136, Issue 5, 2000, Pages 609-616

  Ellis, Charles N ^a   Varani, James ^a   Fisher, Gary J ^a   Zeigler, Mary E ^a   Pershadsingh, Harrihar A ^b,c   Benson, Stephen C ^d   Chi, Yiqing ^a   Kurtz, Theodore W ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KERN MEDICAL CENTER   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; RETINOID; TROGLITAZONE; VITAMIN D;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DIABETES MELLITUS; DISEASE SEVERITY; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; KERATINOCYTE; LIGAND BINDING; MALE; OUTPATIENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PSORIASIS; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SKIN DISEASE; STATISTICAL ANALYSIS;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CHROMANS; DNA PRIMERS; FEMALE; HUMANS; KERATINOCYTES; LIGANDS; MALE; MICE; MICE, SCID; PSORIASIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN DISEASES; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0034030527     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol. 1993;28:422-425.
2. McKay IA, Leigh IM. Altered keratinocyte growth and differentiation in psoriasis. Clin Dermatol. 1995;13:105-114.
3. Barker JN. The pathophysiology of psoriasis. Lancet. 1991;338:227-230.
4. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332: 581-588.
5. McKay IA, Winyard P, Leigh IM, Bustin SA. Nuclear transcription factors: potential targets for new modes of intervention in skin disease. Br J Dermatol. 1994; 131:591-597.
6. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am. 1997;26:553-573.
7. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
8. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR γ. Mol Cell. 1998;1:465-470.
9. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferatoractivated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344-3352.
10. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR γ. Nat Med. 1998;4:1046-1052.
11. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens. 1997;10:440-446.
12. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
13. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol Regul Integr Comp Physiol. 1993;265:R726-R732.
14. Varani J, Nickoloff BMR, Mitra R. Dixit V. Voorhees JJ. All-trans retinoic acid stimulates growth of adult human keratinocytes cultured in growth factor deficient medium, inhibits production of thrombospondin and fibronectin and reduces adhesion. J Invest Dermatol. 1989;93:449-454.
15. ++ on human skin in organ culture. Am J Pathol 1993;142:189-198.
16. Varani J, Kang S.Stoll S, Elder JT. Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects on an antibody to the EGF receptor. Pathobiology. 1998;66:253-259.
17. Varani J, Perone P, Griffiths CE, Inman DR, Fligiel SE, Voorhees JJ. All-trans retinoic acid (RA) stimulates events in organ-cultured human skin that underlie repair: adult skin from sun-protected and sun-exposed sites responds in an identical manner to RA while neonatal foreskin responds differently. J Clin Invest. 1994;94:1747-1756.
18. Varani J. Preservation of human skin structure and function in organ culture. Histol Histopathol. 1998;13:775-783.
19. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM. Severe combined immunodeficiency mouse and human psoriatic skin chimeras: validation of a new animal model. Am J Pathol. 1995;146:580-588.
20. Pershadsingh HA, Sproul JA, Benjamin E, Finnegan JANM Amin NM. Treatment of psoriasis with troglitazone therapy [letter]. Arch Dermatol. 1998;134: 1304-1305.
21. Spencer CM, Markham A. Troglitazone. Drugs. 1997;54:89-101.
22. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM, 15-Deoxy-Δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ Cell. 1995;83:803-812.
23. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83:813-819.
24. Stern RS. Psoriasis. Lancet. 1997;350:349-353.
25. Elbrecht A, Chen YL, Cullinan CA, et al Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Comm. 1996;224:431-437.
26. Mukherjee R, Jow L, Croston GE, Paterniti JR Jr. Identification characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem. 1997;272:8071-8076.
27. Rivier M, Safonova I, Griffiths CEM, Ailhaud G, Micher S. Differential expression of peroxisome proliferator activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol. 1998;111:1116-1121.
28. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982-986.
29. Ibrahimi A, Teboul L, Gaillard D, et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol. 1994;46:1070-1076.
30. Garner WL, Oyatsu Y, Zuccaro C, Rodriquez JL, Smith DJ, Marcelo CL. The effect of essential fatty acid supplementation on keratinocyte replication. Prostaglandins Leukot Essent Fatty Acids. 1995;52:349-355.
31. Grimminger F, Mayser P. Lipid mediators, free fatty acids and psoriasis. Prostaglandins Leukot Essent Fatty Acids. 1995;52:1-15.
32. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 1994;24:170-175.
33. Van Ruissen F, Van de Kerkhof PC, Schalkwijk J. Signal transduction pathways in epidermal proliferation and cutaneous inflammation. Clin Dermatol. 1995;13: 161-190.
34. Altiok S, Xu M, Spiegelman BM. PPAR γ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 1997;11:1987-1998.
35. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors a and γ induces apoptosis in human monocyte-derived macrophages. J Biol Chem, 1998;273:25573-25580.
36. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice, Proc Natl Acad Sci U S A. 1998;95:8806-8811.
37. Komine M, Freedberg IM, Blumenberg M. Regulation of epidermal expression of keratin K17 in inflammatory skin diseases. J Invest Dermatol. 1996;107:569-575.
38. Tomic-Canic M, Komine M, Freedberg IM, Blumenberg M. Epidermal signal transduction and transcription factor activation in activated keratinocytes. J Dermatol Sci. 1998;17:167-181.
39. Boehncke WH, Wortmann S, Kaufmann R, Mielke V. Sterry W. A subset of macrophages located along the basement membrane ("lining cells") is a characteristic histopathological feature of psoriasis. Am J Dermatopathol. 1995;17:139-144.
40. van den Oord JJ, de Wolf-Peeters C. Epithelium-lining macrophages in psoriasis. Br J Dermatol. 1994;130:589-594.
41. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-α, IL-1β and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci. 1997;14: 145-153.
42. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
43. Jiang CY, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
44. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8:159-166.
45. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835-839.
46. Reichrath J, Munssinger T, Kerber A, et al. In situ detection of retinoid-X receptor expression in normal and psoriatic human skin. Br J Dermatol. 1995;133: 168-175.
47. Mukherjee R, Davies PJ, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997;386:407-410.
48. Ellis CN, Kang S, Vinik AI, Grekin RC, Cunningham WJ, Voorhees JJ. Glucose and insulin responses are improved in patients with psoriasis during therapy with etretinate. Arch Dermatol. 1987;123:471-475.
49. Yang XY, Wang LH, Chen T, et al. Activation of human T Iymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists: PPARγ co-association with transcription factor NAFT. J Biol Chem. 2000;275:4541-4544.
50. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364-1371.